Yung Chyung, Scholar Rock CMO (Business Wire)

A dark horse en­trant in­to the spinal mus­cu­lar at­ro­phy field dou­bles its val­ue on some PhII da­ta

The last four years have seen a sud­den ex­plo­sion in treat­ments for spinal mus­cu­lar at­ro­phy, a neu­rode­gen­er­a­tive con­di­tion that once led pa­tients — of­ten young ones …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.